Sugi Predict

Sugi Predict / Targets / GLP1R

GLP1R

Glucagon-like peptide 1 receptor · P43220 · GLP1R on Sugi Atlas →

82,198 patent compounds predicted against GLP1R, 50,999 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL539412 SCHEMBL539412 1.00 20/20
SCHEMBL539413 SCHEMBL539413 1.00 20/20
SCHEMBL539414 SCHEMBL539414 1.00 20/20
SCHEMBL539415 SCHEMBL539415 1.00 20/20
SCHEMBL539504 SCHEMBL539504 1.00 20/20
SCHEMBL539505 SCHEMBL539505 1.00 20/20
SCHEMBL539506 SCHEMBL539506 1.00 20/20
SCHEMBL539507 SCHEMBL539507 1.00 20/20
SCHEMBL539561 SCHEMBL539561 1.00 20/20
SCHEMBL539562 SCHEMBL539562 1.00 20/20
SCHEMBL539563 SCHEMBL539563 1.00 20/20
SCHEMBL539564 SCHEMBL539564 1.00 20/20
SCHEMBL539578 SCHEMBL539578 1.00 20/20
SCHEMBL539620 SCHEMBL539620 1.00 20/20
SCHEMBL539621 SCHEMBL539621 1.00 20/20
SCHEMBL539622 SCHEMBL539622 1.00 20/20
SCHEMBL539623 SCHEMBL539623 1.00 20/20
SCHEMBL539690 SCHEMBL539690 1.00 20/20
SCHEMBL539691 SCHEMBL539691 1.00 20/20
SCHEMBL539693 SCHEMBL539693 1.00 20/20

Clinical trials — most relevant to GLP1R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of GLP-1 on Angiogenesis PHASE4COMPLETED
Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults PHASE4RECRUITING
A Research Study of VCT220 in Adult Chinese Participants With Obesity PHASE3ACTIVE_NOT_RECRUITING
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects PHASE3RECRUITING
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia PHASE2/PHASE3COMPLETED
A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion PHASE3COMPLETED
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET PHASE2/PHASE3COMPLETED
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity PHASE2RECRUITING
A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight PHASE2NOT_YET_RECRUITING
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD PHASE2RECRUITING
The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke PHASE2UNKNOWN
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) PHASE2COMPLETED
Safety and Efficacy of Liraglutide in Parkinson's Disease PHASE2COMPLETED
Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus PHASE1/PHASE2NOT_YET_RECRUITING
Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans PHASE1COMPLETED
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus PHASE1COMPLETED
The Safety, Tolerability and Pharmacokinetic Study of RAY1225 PHASE1COMPLETED
A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects PHASE1COMPLETED
Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Scores nanNOT_YET_RECRUITING
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes nanCOMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention nanNOT_YET_RECRUITING
Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes nanUNKNOWN
Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study nanCOMPLETED
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying nanENROLLING_BY_INVITATION
Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists nanCOMPLETED
Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels nanCOMPLETED
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. nanRECRUITING
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist nanCOMPLETED
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33) nanCOMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a GLP1R binder may also engage these)

ProteinNameSimilarity
O35659 — 1.000 O35659 →
Q61606 — 1.000 Q61606 →
P32301 — 1.000 P32301 →
Q28992 — 1.000 Q28992 →
GCGR Glucagon receptor 1.000 landscape →
Q0P543 — 1.000 Q0P543 →
P43219 — 1.000 P43219 →
Q5FWI2 — 1.000 Q5FWI2 →
P34999 — 1.000 P34999 →
VIPR2 Vasoactive intestinal polypeptide receptor 2 1.000 landscape →
P30083 — 1.000 P30083 →
GIPR Gastric inhibitory polypeptide receptor 1.000 landscape →
P23811 — 0.999 P23811 →
O46502 — 0.999 O46502 →
A0A2Z2U4G9 — 0.999 A0A2Z2U4G9 →
P97751 — 0.999 P97751 →
VIPR1 Vasoactive intestinal polypeptide receptor 1 0.999 landscape →
P43218 — 0.998 P43218 →
Q5IXF8 — 0.998 Q5IXF8 →
GHRHR Growth hormone-releasing hormone receptor 0.998 landscape →
O95838 — 0.996 O95838 →
P30082 — 0.996 P30082 →
P32082 — 0.995 P32082 →
P41588 — 0.995 P41588 →
Q02644 — 0.995 Q02644 →
P35000 — 0.995 P35000 →
Q9Z0W0 — 0.994 Q9Z0W0 →
P25117 — 0.994 P25117 →
Q9IB86 — 0.994 Q9IB86 →
SCTR Secretin receptor 0.993 landscape →